Abstracts tagged "pulmonary"

Abstract Number: 0288 • ACR Convergence 2021
Demographic, Lifestyle, and Clinical Risk Factors for Rheumatoid Arthritis-Associated Bronchiectasis: Role of RA-related Autoantibodies
Gregory McDermott¹, Ritu Gill², Staci Gagne³, Suzanne Byrne³, Weixing Huang³, Lauren Prisco⁴, Alessandra Zaccardelli³, Lily Martin³, Nancy Shadick⁵, Paul Dellaripa³, Tracy Doyle⁶ and Jeffrey Sparks³, ¹Brigham and Women's Hospital, Brookline, MA, ²Beth Israel Deaconess Medical Center, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Pound Ridge, MA, ⁵Brigham & Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital, West Roxbury, MA
Background/Purpose: Bronchiectasis is a known extra-articular manifestation of rheumatoid arthritis (RA) characterized by bronchial damage and excessive mucus production that predispose patients to risk of…
Abstract Number: 0290 • ACR Convergence 2021
Prevalence and Predictors of Mortality in Rheumatoid Arthritis-Related Lung Disease: Results from a Single Center Study
Didem Sahin Eroglu¹, Anil Colaklar², Serdar Baysal³, Murat Torgutalp¹, Asaf Baygul⁴, Serdar Sezer¹, Emine Aydemir Guloksuz¹, Mehmet Yuksel¹, Mucteba Yayla¹, Emine Uslu yurteri⁵, Caglar Uzun², Ozlem Ozdemir kumbasar⁴, Murat Turgay¹, Kinikli Gulay¹ and Askin Ates¹, ¹Ankara University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ²Ankara University Faculty of Medicine, Department of Radiology, Ankara, Turkey, ³Ankara University Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey, ⁴Ankara University Faculty of Medicine, Department of Pulmonology, Ankara, Turkey, ⁵Hatay Training and Research Hospital, Hatay, Turkey
Background/Purpose: Rheumatoid arthritis-related lung disease (RA-LD) is a common manifestation of rheumatoid arthritis (RA) and associated with excess mortality. Many studies to date were focused…
Abstract Number: 0291 • ACR Convergence 2021
IgA Anti-Cyclic Citrullinated Peptide Antibodies in Bronchoalveolar Lavage Fluid from Patients with Idiopathic Pulmonary Fibrosis Are Associated with Reduced Mortality
Scott Matson¹, Candace Cephers², Timothy Wilson³, Valerie Minarchick³, Kevin Brown⁴, Joshua Solomon⁴ and Kristen Demoruelle⁵, ¹University of Kansas, Kansas City, MO, ²St Joseph Hospital, Internal Medicine, Denver, CO, ³University of Colorado, Denver, CO, ⁴National Jewish Health, Denver, CO, ⁵University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Idiopathic pulmonary fibrosis (IPF) is a form of interstitial lung disease (ILD) that shares many clinical features with rheumatoid arthritis (RA) associated ILD. Our…
Abstract Number: 0497 • ACR Convergence 2021
Efficacy in Patient Subgroups in the INCREASE Trial, a Phase III Trial to Evaluate Inhaled Treprostinil in Patients with Pulmonary Hypertension Due to Parenchymal Lung Disease
Victor Tapson¹, Steven Nathan², Reda Girgis³, James Runo⁴, Remzi Bag⁵, Arunabh Talwar⁶, Peter Smith⁷, Lisa Edwards⁷, Christine Park⁷ and Aaron Waxman⁸, ¹Cedars-Sinai, Los Angeles, CA, ²Inova Fairfax, Falls Church, VA, ³Michigan State University, Lansing, MI, ⁴University of Wisconsin, Madison, WI, ⁵University of Chicago, Chicago, IL, ⁶Hofstra Northwell School of Medicine, Hempstead, NY, ⁷United Therapeutics Corporation, Durham, NC, ⁸Brigham and Women's Hospital, Boston, MA
Background/Purpose: INCREASE was a 16-week trial evaluating the safety and efficacy of inhaled treprostinil (iTRE) in patients with pulmonary hypertension associated with interstitial lung disease…
Abstract Number: 0505 • ACR Convergence 2021
Risk of Venous and Arterial Thromboembolism in Patients with Giant Cell Arteritis And/or Polymyalgia Rheumatica: A Veterans Health Administration Population-Based Study in the United States
Despina Michailidou¹, Tianyu Zhang², Pavlos Stamatis³ and Bernard Ng⁴, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Biostatistics, University of Washington, Seattle, WA, ³Lund University, Lund, Sweden, ⁴Rheumatology Section, VA Puget Sound HCS, University of Washington, Seattle, WA
Background/Purpose: Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are two chronic systemic inflammatory diseases that primarily affect elderly women. Both diseases can be complicated…
Abstract Number: 1002 • ACR Convergence 2021
Nerve and Airway-associated Tissue Resident Pulmonary Macrophages Limit Infiltration and Alter Phenotype of Infiltrating Monocytes and Fibrocytes to Reduce Pulmonary Fibrosis
Robert Freilich¹ and Kamal Khanna², ¹New York University Department of Rheumatology, New York, NY, ²New York University Department of Rheumatology & Microbiology, New York, NY
Background/Purpose: Macrophages and monocytes are increasingly implicated in the pathogenesis of autoimmune induced pulmonary fibrosis. In addition to the well-recognized classes of tissue resident macrophages…
Abstract Number: 1100 • ACR Convergence 2021
Pulmonary Arterial Hypertension in Adult-Onset Still’s Disease: A Case Series of 13 Patients
Stéphane Mitrovic¹, athénaïs Boucly², Estibaliz Lazaro³, Nicolas SCHLEINITZ⁴, Coralie Bloch-Queyrat⁵, Christine Christides⁶, Jacques Pouchot⁷, marc humbert², David Montani², laurent savale², Xavier Jaïs², Olivier Sitbon² and Bruno Fautrel⁸, ¹Pitié Salpêtrière Hospital - Institut Mutaliste Montsouris, Paris, France, ²Pneumology Department, Bicêtre Hospital, Assistance Publique – Hôpitaux de Paris, Kremlin-Bicêtre, France, ³Internal Medicine Department, CHU Bordeaux, Pessac, France, ⁴Internal Medicine Department, Hôpital Timone, APHM, Marseille, France, ⁵Internal Medicine Department, Avicennes Hospital, APHP, Bobigny, France, ⁶Internal Medicine Department, CH Avignon, Avignon, France, ⁷AP-HP, RUEIL-MALMAISON, France, ⁸Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France
Background/Purpose: Pulmonary Arterial Hypertension (PAH) is a rare but potentially fatal complication of Adult-Onset Still's Disease (AOSD). To date, only isolated observations have been published.…
Abstract Number: 1370 • ACR Convergence 2021
Complement Factor D and Factor H Represent Disease and Severity Biomarkers for Systemic Sclerosis Associated Pulmonary Arterial Hypertension (SSc-PAH)
Roberta G Marangoni¹, Changyong Feng¹, Ashley Frazer-Abel², Stephen Tomlinson³, Amy Wielgosz¹, Katie Lutz⁴, Michael Pauciulo⁴, William Nichols⁴, V. Michael Holers⁵, Christopher Ritchlin⁶, R James White III¹ and Benjamin Korman¹, ¹University of Rochester, Rochester, NY, ²University of Colorado Denver, Colorado, CO, ³Medical University of South Carolina, Charleston, SC, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵University of Colorado, Denver, CO, ⁶Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Pulmonary arterial hypertension (PAH) is a severe vascular complication of systemic sclerosis (SSc) and a major cause of mortality. Despite significant advances in the…
Abstract Number: L04 • ACR Convergence 2020
Influenza Adverse Events in Patients with Rheumatoid Arthritis in the Tofacitinib Clinical Program
Kevin L Winthrop¹, Arne Yndestad², Dan Henrohn³, Hyejin Jo⁴, Sara Marsal⁵, Maria Galindo⁶, Annette Diehl⁷, Andrea B Shapiro⁸ and Stanley B Cohen⁹, ¹Oregon Health & Science University, Portland, OR, ²Pfizer Inc, Oslo, Norway, ³Pfizer Inc, Sollentuna, Sweden, ⁴Syneos Health, Raleigh, NC, ⁵Vall d’Hebron Hospital, Barcelona, Spain, ⁶Rheumatology Unit, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁷Pfizer Inc, Collegeville, PA, ⁸Pfizer Inc, Peapack, NJ, ⁹Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Patients (pts) with RA have increased susceptibility to seasonal influenza and its complications.1 The COVID-19 pandemic highlights the need to understand acute respiratory RNA…
Abstract Number: 0491 • ACR Convergence 2020
Relationship Between Rheumatoid Arthritis and Pulmonary Function in the UK Biobank
Lauren C. Prisco¹, Matthew Moll¹, Jiaqi Wang², Weixing Huang³, Lily Martin¹, Vanessa Kronzer⁴, Sicong Huang², Edwin Silverman², Tracy J. Doyle⁵, Michael Cho⁵ and Jeffrey Sparks⁶, ¹Brigham and Women's Hospital, Boston, ²Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, ⁴Mayo Clinic, Rochester, MN, ⁵Brigham and Women's Hospital, West Roxbury, MA, ⁶Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Established pulmonary manifestations of RA include restrictive processes such as interstitial lung disease and obstructive processes such as bronchiectasis, but clinically detected forms of…
Abstract Number: 1694 • ACR Convergence 2020
Risk Factors Associated with Pneumocystis Jirovecii Pneumonia in Juvenile Myositis in North America
Sara Sabbagh¹, Jessica Neely², Albert Chow³, Marietta DeGuzman⁴, Jamie Lai⁵, Svetlana Lvovich⁶, Tara McGrath⁷, Maria Pereira⁸, Iago Pinal-Fernandez⁹, Jordan Roberts¹⁰, Kelly Rouster-Stevens¹¹, Heinrike Schmeling¹², Anjali Sura¹³, Gabriel Tarshish¹⁴, Lori Tucker¹⁵, Lisa G. Rider¹⁶ and Susan Kim¹⁷, ¹Medical College of Wisconsin, Fox Point, WI, ²UCSF, San Francisco, CA, ³Loma Linda University, San Bernardino, CA, ⁴Baylor College of Medicine, Houston, ⁵University of Colorado, The Woodlands, TX, ⁶St Christopher's Hospital for Children, Philadelphia, PA, ⁷University of British Columbia, Vancouver, BC, Canada, ⁸Baylor College of Medicine, Houston, TX, ⁹National Institutes of Health, Bethesda, MD, ¹⁰Boston Children's Hospital, Boston, MA, ¹¹Emory University/Children's Healthcare of Atlanta, Atlanta, GA, ¹²University of Calgary, Calgary, AB, Canada, ¹³Upstate University Hospital, Syracuse, NY, ¹⁴Children's Hospital at Montefiore, New York, NY, ¹⁵BC Children's Hospital, Vancouver, BC, Canada, ¹⁶Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Garrett Park, MD, ¹⁷UCSF Benioff Children's Hospital, San Francisco, CA
Background/Purpose: Pneumocystis jirovecii pneumonia (PJP) is associated with significant morbidity and mortality in adult myositis patients; however, few studies have examined PJP in juvenile myositis…
Abstract Number: 0520 • ACR Convergence 2020
Antiphospholipid Antibodies and Thrombotic Events in COVID-19 Patients Hospitalized in Medicine Ward
Alexandre Le Joncour¹, Corinne Frere¹, Isabelle Martin-Toutain¹, Paul Gougis¹, Pascale Ghillani-Dalbin¹, Georgina Maalouf¹, Matheus Vieira¹, Anne-Genevieve Marcelin¹, Joe-Elie Salem¹, Yves Allenbach², David Saadoun³, Olivier Benveniste⁴ and Patrice Cacoub¹, ¹APHP, paris, France, ²Sorbonne Université, Paris, Ile-de-France, France, ³AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Centre national de références Maladies Autoimmunes et systémiques rares et Maladies Autoinflammatoires rares, PAris, France, ⁴Sorbonne Université, paris, France
Background/Purpose: A high prevalence of thrombotic events has been reported in critically ill COVID-19 patients but data on the prevalence of thrombosis in ward patients…
Abstract Number: 1695 • ACR Convergence 2020
Anti-Melanoma Differentiation Associated Protein 5 (MDA5) Positive Juvenile Dermatomyositis: Focus on the Lung
David Moreno McNeill¹, Miriah Gillispie-Taylor², Kevin Baszis³, Edouard Sayad¹, Manuel Silva Carmona¹ and Tiphanie Vogel¹, ¹Baylor College of Medicine/Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Houston, ³Washington Univ School of Medicine, St Louis, MO
Background/Purpose: A subset of juvenile dermatomyositis (JDM), clinically amyopathic dermatomyositis (CADM), is uncommon and mainly described in adults. CADM is classically characterized by skin ulcerations,…
Abstract Number: 0785 • ACR Convergence 2020
Identification of Recruited CCR2+ Inflammatory Monocytes in a Mouse Model of RA-associated Lung Disease with Potential Role for resolvin-D1 in Reducing Monocyte Inflammatory Responses
Austin Barry¹, Geoffrey Thiele¹, Ted Mikuls¹, Michael Duryee¹, Amy Nelson¹, Rohit Gaurav¹, Bryant England¹ and Jill Poole¹, ¹University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Patients with rheumatoid arthritis (RA) are at an increased risk for comorbid chronic lung disease, with premature mortality. Therapies for RA-associated lung disease are…
Abstract Number: 1908 • ACR Convergence 2020
Establishment of iPSc and Differentiated Endothelial Cells of Systemic Sclerosis Associated Pulmonary Arterial Hypertension ; Functional and Molecular Analysis
Yuki Kudo¹, Masaru Kato², Yuhei Shibata¹, Michihito Kono², Yuichiro Fujieda², Olga Amengual², Kenji Oku² and Tatsuya Atsumi³, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ²Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, ³Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapparo, Hokkaido, Japan
Background/Purpose: Pulmonary arterial hypertension (PAH) occurs either primarily or in association with other diseases such as connective tissue diseases. PAH associated with systemic sclerosis (SSc-PAH)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].